Chang et al. [31] reported that mTOR inhibitors enhance radiosensitivity through inducing apoptosis, reducing autophagy, and suppressing DNA repair proteins in radioresistant prostate cancer cells. Here, XRCC6P5 is linked to prostate carcinoma.